Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control for Primary Indeterminate Lesions or Small Choroidal Melanoma

Overview

About this study

The purpose of this study is to determine the efficacy and safety of bel-sar compared to sham control for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)

- Have no evidence of metastatic disease confirmed by imaging

- Be treatment naive for IL/CM (subjects who received PDT may be eligible)

Exclusion Criteria:

- Have known contraindications or sensitivities to the study drug or laser

- Active ocular infection or disease

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/26/23. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lauren Dalvin, M.D.

Closed for enrollment

Contact information:

Laura Taylor C.O.A.

(507) 422-2779

Taylor.Laura2@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20557272

Mayo Clinic Footer